Next-generation re-sequencing of genes involved in increased platelet reactivity in diabetic patients on acetylsalicylic acid

Marek Postula, Piotr K. Janicki, Ceren Eyileten, Marek Rosiak, Agnieszka Kaplon-Cieslicka, Shigekazu Sugino, Radosław Wilimski, Dariusz A. Kosior, Grzegorz Opolski, Krzysztof J. Filipiak, Dagmara Mirowska-Guzel

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The objective of this study was to investigate whether rare missense genetic variants in several genes related to platelet functions and acetylsalicylic acid (ASA) response are associated with the platelet reactivity in patients with diabetes type 2 (T2D) on ASA therapy. Fifty eight exons and corresponding introns of eight selected genes, including PTGS1, PTGS2, TXBAS1, PTGIS, ADRA2A, ADRA2B, TXBA2R, and P2RY1 were re-sequenced in 230 DNA samples from T2D patients by using a pooled PCR amplification and next-generation sequencing by Illumina HiSeq2000. The observed non-synonymous variants were confirmed by individual genotyping of 384 DNA samples comprising of the individuals from the original discovery pools and additional verification cohort of 154 ASA-treated T2DM patients. The association between investigated phenotypes (ASA induced changes in platelets reactivity by PFA-100, VerifyNow and serum thromboxane B2 level [sTxB2]), and accumulation of rare missense variants (genetic burden) in investigated genes was tested using statistical collapsing tests. We identified a total of 35 exonic variants, including 3 common missense variants, 15 rare missense variants, and 17 synonymous variants in 8 investigated genes. The rare missense variants exhibited statistically significant difference in the accumulation pattern between a group of patients with increased and normal platelet reactivity based on PFA-100 assay. Our study suggests that genetic burden of the rare functional variants in eight genes may contribute to differences in the platelet reactivity measured with the PFA-100 assay in the T2DM patients treated with ASA.

Original languageEnglish (US)
Pages (from-to)357-364
Number of pages8
JournalPlatelets
Volume27
Issue number4
DOIs
StatePublished - May 18 2016

Fingerprint

Aspirin
Blood Platelets
Genes
Thromboxane B2
DNA
Cyclooxygenase 2
Introns
Type 2 Diabetes Mellitus
Exons
Phenotype
Polymerase Chain Reaction
Serum
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Postula, Marek ; Janicki, Piotr K. ; Eyileten, Ceren ; Rosiak, Marek ; Kaplon-Cieslicka, Agnieszka ; Sugino, Shigekazu ; Wilimski, Radosław ; Kosior, Dariusz A. ; Opolski, Grzegorz ; Filipiak, Krzysztof J. ; Mirowska-Guzel, Dagmara. / Next-generation re-sequencing of genes involved in increased platelet reactivity in diabetic patients on acetylsalicylic acid. In: Platelets. 2016 ; Vol. 27, No. 4. pp. 357-364.
@article{0f59d4de453940869002b268c36c558e,
title = "Next-generation re-sequencing of genes involved in increased platelet reactivity in diabetic patients on acetylsalicylic acid",
abstract = "The objective of this study was to investigate whether rare missense genetic variants in several genes related to platelet functions and acetylsalicylic acid (ASA) response are associated with the platelet reactivity in patients with diabetes type 2 (T2D) on ASA therapy. Fifty eight exons and corresponding introns of eight selected genes, including PTGS1, PTGS2, TXBAS1, PTGIS, ADRA2A, ADRA2B, TXBA2R, and P2RY1 were re-sequenced in 230 DNA samples from T2D patients by using a pooled PCR amplification and next-generation sequencing by Illumina HiSeq2000. The observed non-synonymous variants were confirmed by individual genotyping of 384 DNA samples comprising of the individuals from the original discovery pools and additional verification cohort of 154 ASA-treated T2DM patients. The association between investigated phenotypes (ASA induced changes in platelets reactivity by PFA-100, VerifyNow and serum thromboxane B2 level [sTxB2]), and accumulation of rare missense variants (genetic burden) in investigated genes was tested using statistical collapsing tests. We identified a total of 35 exonic variants, including 3 common missense variants, 15 rare missense variants, and 17 synonymous variants in 8 investigated genes. The rare missense variants exhibited statistically significant difference in the accumulation pattern between a group of patients with increased and normal platelet reactivity based on PFA-100 assay. Our study suggests that genetic burden of the rare functional variants in eight genes may contribute to differences in the platelet reactivity measured with the PFA-100 assay in the T2DM patients treated with ASA.",
author = "Marek Postula and Janicki, {Piotr K.} and Ceren Eyileten and Marek Rosiak and Agnieszka Kaplon-Cieslicka and Shigekazu Sugino and Radosław Wilimski and Kosior, {Dariusz A.} and Grzegorz Opolski and Filipiak, {Krzysztof J.} and Dagmara Mirowska-Guzel",
year = "2016",
month = "5",
day = "18",
doi = "10.3109/09537104.2015.1109071",
language = "English (US)",
volume = "27",
pages = "357--364",
journal = "Platelets",
issn = "0953-7104",
publisher = "Informa Healthcare",
number = "4",

}

Postula, M, Janicki, PK, Eyileten, C, Rosiak, M, Kaplon-Cieslicka, A, Sugino, S, Wilimski, R, Kosior, DA, Opolski, G, Filipiak, KJ & Mirowska-Guzel, D 2016, 'Next-generation re-sequencing of genes involved in increased platelet reactivity in diabetic patients on acetylsalicylic acid', Platelets, vol. 27, no. 4, pp. 357-364. https://doi.org/10.3109/09537104.2015.1109071

Next-generation re-sequencing of genes involved in increased platelet reactivity in diabetic patients on acetylsalicylic acid. / Postula, Marek; Janicki, Piotr K.; Eyileten, Ceren; Rosiak, Marek; Kaplon-Cieslicka, Agnieszka; Sugino, Shigekazu; Wilimski, Radosław; Kosior, Dariusz A.; Opolski, Grzegorz; Filipiak, Krzysztof J.; Mirowska-Guzel, Dagmara.

In: Platelets, Vol. 27, No. 4, 18.05.2016, p. 357-364.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Next-generation re-sequencing of genes involved in increased platelet reactivity in diabetic patients on acetylsalicylic acid

AU - Postula, Marek

AU - Janicki, Piotr K.

AU - Eyileten, Ceren

AU - Rosiak, Marek

AU - Kaplon-Cieslicka, Agnieszka

AU - Sugino, Shigekazu

AU - Wilimski, Radosław

AU - Kosior, Dariusz A.

AU - Opolski, Grzegorz

AU - Filipiak, Krzysztof J.

AU - Mirowska-Guzel, Dagmara

PY - 2016/5/18

Y1 - 2016/5/18

N2 - The objective of this study was to investigate whether rare missense genetic variants in several genes related to platelet functions and acetylsalicylic acid (ASA) response are associated with the platelet reactivity in patients with diabetes type 2 (T2D) on ASA therapy. Fifty eight exons and corresponding introns of eight selected genes, including PTGS1, PTGS2, TXBAS1, PTGIS, ADRA2A, ADRA2B, TXBA2R, and P2RY1 were re-sequenced in 230 DNA samples from T2D patients by using a pooled PCR amplification and next-generation sequencing by Illumina HiSeq2000. The observed non-synonymous variants were confirmed by individual genotyping of 384 DNA samples comprising of the individuals from the original discovery pools and additional verification cohort of 154 ASA-treated T2DM patients. The association between investigated phenotypes (ASA induced changes in platelets reactivity by PFA-100, VerifyNow and serum thromboxane B2 level [sTxB2]), and accumulation of rare missense variants (genetic burden) in investigated genes was tested using statistical collapsing tests. We identified a total of 35 exonic variants, including 3 common missense variants, 15 rare missense variants, and 17 synonymous variants in 8 investigated genes. The rare missense variants exhibited statistically significant difference in the accumulation pattern between a group of patients with increased and normal platelet reactivity based on PFA-100 assay. Our study suggests that genetic burden of the rare functional variants in eight genes may contribute to differences in the platelet reactivity measured with the PFA-100 assay in the T2DM patients treated with ASA.

AB - The objective of this study was to investigate whether rare missense genetic variants in several genes related to platelet functions and acetylsalicylic acid (ASA) response are associated with the platelet reactivity in patients with diabetes type 2 (T2D) on ASA therapy. Fifty eight exons and corresponding introns of eight selected genes, including PTGS1, PTGS2, TXBAS1, PTGIS, ADRA2A, ADRA2B, TXBA2R, and P2RY1 were re-sequenced in 230 DNA samples from T2D patients by using a pooled PCR amplification and next-generation sequencing by Illumina HiSeq2000. The observed non-synonymous variants were confirmed by individual genotyping of 384 DNA samples comprising of the individuals from the original discovery pools and additional verification cohort of 154 ASA-treated T2DM patients. The association between investigated phenotypes (ASA induced changes in platelets reactivity by PFA-100, VerifyNow and serum thromboxane B2 level [sTxB2]), and accumulation of rare missense variants (genetic burden) in investigated genes was tested using statistical collapsing tests. We identified a total of 35 exonic variants, including 3 common missense variants, 15 rare missense variants, and 17 synonymous variants in 8 investigated genes. The rare missense variants exhibited statistically significant difference in the accumulation pattern between a group of patients with increased and normal platelet reactivity based on PFA-100 assay. Our study suggests that genetic burden of the rare functional variants in eight genes may contribute to differences in the platelet reactivity measured with the PFA-100 assay in the T2DM patients treated with ASA.

UR - http://www.scopus.com/inward/record.url?scp=84947770817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947770817&partnerID=8YFLogxK

U2 - 10.3109/09537104.2015.1109071

DO - 10.3109/09537104.2015.1109071

M3 - Article

C2 - 26599574

AN - SCOPUS:84947770817

VL - 27

SP - 357

EP - 364

JO - Platelets

JF - Platelets

SN - 0953-7104

IS - 4

ER -